Future directions with taxane therapy

F. Cabral, Edward Trimble, E. Reed, G. Sarosy

Research output: Contribution to journalReview article

Abstract

The potential biochemical and genetic mechanisms by which a cell might experience a decreased sensitivity to taxanes and other drugs of this class are discussed in the first part of this article. The use of taxanes in the current gynecologic-oncologic clinical setting is reviewed with special consideration given to the pharmacokinetics of taxane in relation to dose intensity and length of administration.

Original languageEnglish (US)
Pages (from-to)21-41
Number of pages21
JournalHematology/Oncology Clinics of North America
Volume13
Issue number1
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Taxoids
Molecular Biology
Pharmacokinetics
Therapeutics
Pharmaceutical Preparations
taxane
Direction compound

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Future directions with taxane therapy. / Cabral, F.; Trimble, Edward; Reed, E.; Sarosy, G.

In: Hematology/Oncology Clinics of North America, Vol. 13, No. 1, 1999, p. 21-41.

Research output: Contribution to journalReview article

Cabral, F. ; Trimble, Edward ; Reed, E. ; Sarosy, G. / Future directions with taxane therapy. In: Hematology/Oncology Clinics of North America. 1999 ; Vol. 13, No. 1. pp. 21-41.
@article{b6c735b59c994f0db81c482752359a05,
title = "Future directions with taxane therapy",
abstract = "The potential biochemical and genetic mechanisms by which a cell might experience a decreased sensitivity to taxanes and other drugs of this class are discussed in the first part of this article. The use of taxanes in the current gynecologic-oncologic clinical setting is reviewed with special consideration given to the pharmacokinetics of taxane in relation to dose intensity and length of administration.",
author = "F. Cabral and Edward Trimble and E. Reed and G. Sarosy",
year = "1999",
doi = "10.1016/S0889-8588(05)70152-0",
language = "English (US)",
volume = "13",
pages = "21--41",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Future directions with taxane therapy

AU - Cabral, F.

AU - Trimble, Edward

AU - Reed, E.

AU - Sarosy, G.

PY - 1999

Y1 - 1999

N2 - The potential biochemical and genetic mechanisms by which a cell might experience a decreased sensitivity to taxanes and other drugs of this class are discussed in the first part of this article. The use of taxanes in the current gynecologic-oncologic clinical setting is reviewed with special consideration given to the pharmacokinetics of taxane in relation to dose intensity and length of administration.

AB - The potential biochemical and genetic mechanisms by which a cell might experience a decreased sensitivity to taxanes and other drugs of this class are discussed in the first part of this article. The use of taxanes in the current gynecologic-oncologic clinical setting is reviewed with special consideration given to the pharmacokinetics of taxane in relation to dose intensity and length of administration.

UR - http://www.scopus.com/inward/record.url?scp=0033044492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033044492&partnerID=8YFLogxK

U2 - 10.1016/S0889-8588(05)70152-0

DO - 10.1016/S0889-8588(05)70152-0

M3 - Review article

C2 - 10080068

AN - SCOPUS:0033044492

VL - 13

SP - 21

EP - 41

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 1

ER -